Healthegy Inc.

03/20/2020

Healthegy Inc.'s cover photo

05/13/2019

Make sure to tune into the newest episode of Healthcare is Hard: A Podcast for Insiders, released just today. LRVHealth's Keith Figlioli sat down with Gary Bisbee, Co-Founder and Executive Chairman of The Health Management Academy, to discuss how value-based care is poised for an evolution, the challenges health systems execs will face reconciling the “right thing” with revenue, and more. https://buff.ly/2VoUtDK

04/17/2019

Register to Attend | Respiratory Innovation Summit

Join us at the May 17 Respiratory Innovation Summit to understand the forces that are driving adoption of new tools being used in interventional lung procedures.

Attendees will hear an overview of the interventional pulmonology space, watch presentations by some of the sector’s leading start-ups, and enjoy a discussion between clinicians and start-up executives.

Go to www.attendris.com/register to sign up for the May 17 event.

RIS is organized by Healthegy, a creator of conferences and content that accelerate healthcare innovation. Healthegy is partnering with the American Thoracic Society to host RIS prior to the start of the ATS International Conference. The two events require separate registrations.

The Respiratory Innovation Summit (RIS) unites the innovators, investors and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways. Register today to join this group.

04/15/2019

Many hands put a great deal of work into creating this agenda for the May 17 Respiratory Innovation Summit. I couldn't be happier with the outcome or more grateful to everyone who is taking part. I hope you'll join us on May 17 in Dallas. Register at attendris.com

04/04/2019

Don't miss this ! Register at AttendRIS.com

03/29/2019

To address the significant challenges and opportunities facing women’s health, we have assembled a panel of clinical and industry leaders at the upcoming Aesthetics Innovation Summit on May 15th in New Orleans.
https://buff.ly/2H8QqZ3

03/01/2019

Medtech Incubator NXT Biomedical Shows Stan Rowe Is Great at Innovation, Bad at “Retirement” - Medtech Conference

Few have witnessed from as many angles as Stan Rowe. He's been at big companies, small companies and now a well-heeled incubator, NXT Biomedical. Easy to have a great conversation with someone like that.

After leading a long, distinguished and successful career in Medtech Innovation, Stan Rowe chose a familiar, if not unusual, spot to “retire” – he co-founded NXT Biomedical, an incubator backed by Deerfield Capital and Johnson & Johnson.

02/18/2019

Why Attend AIS?

What is AIS all about? Aubrey Rankin, CEO of HintMD shares why AIS has become the premier meeting in Aesthetics.

American Society for Aesthetic Plastic Surgery (ASAPS)

02/14/2019

What Is IHI’s “Triple Aim?” Founders Don Berwick, Maureen Bisognano Lay Out Campaign for Change

Released just today is episode 4 of . talks with and , who help to drive results in and improvement worldwide through

Achieving the “Triple Aim” of better care, better health, and lower per capita cost is the ultimate goal for creating real change in health. But as the Institute for Healthcare Improvement’s Don Berwick and Maureen Bisognano explain on Healthcare is Hard: A Podcast for Insiders, creating inspi...

02/13/2019

EvolusAesthetic

Congratulations to EvolusAesthetic on receiving FDA approval for Jeuveau (prabotulinumtoxinA-xvfs) for injection!

Listen to David Moatazedi, President and Chief Executive Officer of Evolus, speak at The Aesthetics Innovation Summit on May 15, 2019, register here: https://attendais.com/

5th-grade birthday party? Pop-queen concert? FDA approval? All of the above? Visit Evolus.com to find out... or just keep watching us party.

02/05/2019

William Meury, EVP, and Chief Commercial Officer talks shop with AI Podcast Co-Host Grant Stevens, MD. In this conversation at Stevens’ office in Marina Del Rey, Calif., the two aesthetics leaders swap insights on the meteoric growth of the aesthetics industry. Meury also dishes on Allergan’s M&A strategy including the fast-acting neurotoxins developed by recently acquired Bonti. He also gives his assessment of the emerging competition for Allergan’s anchor product, Botox. Also, why is Allergan building an Aesthetics Innovation center in China? https://bit.ly/2DaLVcE

02/04/2019

Medtech Conference

Jonathan Norris, managing director of Silicon Valley Bank, points to rising investments in Medtech.

The Medtech Conference is an Unparalleled Gathering of the Leading Innovators, Investors and Executives from around the Nation Discussing the Timeliest Issues and Opportunities.

02/04/2019

Piper Jaffray Analyst David Amesllem See Growth, Change Coming in Aesthetics Industry

David Amsellem, Managing Director and Senior Research analyst at Piper Jaffray, reveals the changing demographics of the aesthetics market, the rise of new neuromodulators, and other coming changes to this growing industry. https://attendais.com/

David Amsellem, managing director and senior research analyst at Piper Jaffray, reveals the changing demographics of the aesthetics market, the rise of new n...

02/01/2019

SVB’s Jonathan Norris sees strong returns for Medtech Investors

Jonathan Norris, managing director of Silicon Valley Bank, explains how Medtech M&A is producing strong venture returns. Watch his data-rich presentation at the May 29-30 Medtech Conference. www.medtechconference.com.

Jonathan Norris, managing director of Silicon Valley Bank, explains how Medtech M&A is producing str...

01/31/2019

SVB’s Jonathan Norris sees promising increases in the Medtech Investment

Jonathan Norris, managing director of Silicon Valley Bank, points to rising investments in Medtech start-ups including robotics, neurology, oncology and other areas. Watch his overview of 2018 and what will the exit opportunities be in 2019? Watch his data-rich presentation at the May 29-30 Medtech Conference. www.medtechconference.com.

Jonathan Norris, managing director of Silicon Valley Bank, points to rising investments in Medtech s...

12/22/2018

Happy Holidays from Healthegy! We appreciate your participation and support of our 2018 Conferences. Wishing you a prosperous New Year!

12/21/2018

What will 2019 bring to ? The best way to figure that out is to understand what the extraordinary events of 2018. Download OIS co-chair Emmett Cunningham's EXPANDED Year in Review to see a complete wrap up of FDA approvals, venture financings and other benchmarks. https://ois.net/year-in-review/

12/21/2018

At this time of year we express gratitude to all of our conference partners and participants for supporting our mission to be a catalyst for healthcare innovation by connecting great ideas with the people and funding to bring them to life.

Happy Holidays and a Healthegy New Year!

12/19/2018

HanAll Biopharma ready to Engage Phase III Trials

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., outlines the company’s growing pipeline. In ophthalmology, HanAll, which is based in Seoul, has completed Phase II trials of HL036, an anti-TNF-alpha protein, for the treatment of . Applied twice a day, HL036 was shown to reduce symptoms and signs. The company is collaborating with Daewoong Pharmaceutical. HanAll may also test HL036 as a treatment for anterior uveitis, Wet AMD, and DME.

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., outlines the company’s growing pipel...

12/18/2018

Can HumanOptics change “Human optics history” with its artificial iris?

HumanOptics CEO Pierre Billardon explains how the company’s CUSTOMFLEX ARTIFICIALIRIS can mimic the color and structure of an IRIS that’s been damaged by aniridia. How did HumanOptics secure FDA approval in only six months?

CEO Pierre Billardon, PhD, answers Three Critical Questions about HumanOptics’ CUSTOMFLEX ARTIFICIALIRIS, a med...

12/18/2018

Can OcuFLOW Save Billions in Drug Costs?

Can OcuFLOW save the healthcare system billions of dollars? In this interview and presentation, Theresa Kramer, MD, founder, CEO, and CMO of OcuFLOW, says company’s test of Choroidal Blood Flow could help physicians protect vision of people suffering from AMD, Diabetic Retinopathy, and Glaucoma. The technology also could save the healthcare system billions of dollars annually. The company is hoping to raise a Seed and Series A round in 2019.

Theresa Kramer, MD, founder, CEO, and CMO of OcuFLOW, says the testing of Choroidal Blood Flow could help optometrists and ophthalmologists delay visual impa...

12/17/2018

Jasek on NEXAGON: “The Most Exciting Drug” of My Career

Mark Jasek, PhD, chief scientific officer of Eyevance Pharmaceuticals, answers three critical questions about Eyevance and NEXAGON, a first-in-class unmodified antisense oligodeoxynucleotide the company licensed from OcuNexus Therapeutics. Dr. Jasek says NEXAGON is the “most exciting drug I’ve ever worked with in my career.” The company intends to begin a Phase IIb trial early next year to test NEXAGON as a potential treatment for persistent corneal epithelial defect (PED) caused by thermal or chemical burns.

Mark Jasek, PhD, chief scientific officer of Eyevance Pharmaceuticals, answers three critical questions about Eyevance and NEXAGON, a first-in-class unmodifi...

12/17/2018

OcuMedic Brings Simple Solution to Eye Drop Delivery

Keith D. Ignotz, president and CEO of OcuMedic Inc., explains how the company is looking to upend the eye drop delivery market in ophthalmology. OcuMedic is developing contact lenses and clear corneal bandages to deliver anti-inflammatories and treatment for Dye Eye Disease directly to patients’ eyes. The lenses and bandages could seize a piece of the $16 billion eye drop market. The company operates in a competitive space, but Ignotz identifies the strength of OcuMedic’s position. The firm currently is seeking to raise a $4 million Series A.

Keith D. Ignotz, president and CEO of OcuMedic Inc., explains how the company is looking to upend the...

12/13/2018

Jasek on NEXAGON: “The Most Exciting Drug” of My Career

Mark Jasek, PhD, chief scientific officer of Eyevance Pharmaceuticals, answers three critical questions about Eyevance and NEXAGON, a first-in-class unmodified antisense oligodeoxynucleotide the company licensed from OcuNexus Therapeutics. Dr. Jasek tells OIS Companies to Watch that NEXAGON is the “most exciting drug I’ve ever worked with in my career.”

Mark Jasek, PhD, chief scientific officer of Eyevance Pharmaceuticals, answers three critical questions about Eyevance and NEXAGON, a first-in-class unmodifi...

12/13/2018

OIS Podcast visits with Eric Donnenfeld, MD, to review the field of innovative dry eye companies. Where are they in their clinical trials? What products have him most excited? What could the future of dry eye be? https://ois.net/eric-donnenfeld-md-handicaps-a-crowded-field-in-the-race-to-develop-the-next-dry-eye-blockbuster/

12/12/2018

Can HumanOptics change “Human optics history” with its artificial iris?

HumanOptics CEO Pierre Billardon explains how the company’s CUSTOMFLEX ARTIFICIALIRIS can mimic the color and structure of an IRIS that’s been damaged by aniridia. How did HumanOptics secure FDA approval in only six months?

CEO Pierre Billardon, PhD, answers Three Critical Questions about HumanOptics’ CUSTOMFLEX ARTIFICIALIRIS, a med...

12/12/2018

HanAll Biopharma readying for Phase III Dry Eye Trial

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., answers Three Critical Questions about the company’s lead product, HL036, which will begin Phase III clinical trials as a treatment for .

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., answers Three Critical Questions abo...

12/11/2018

Healthegy Inc.'s cover photo

12/11/2018

No one sees as well as OIS Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH. Download his highly anticipated Year in Review for free! This report contains even more data than his report. https://ois.net/year-in-review/

12/10/2018

OcuFLOW Working to Measure Choroidal Blood Flow

Can OcuFLOW save the healthcare system billions of dollars? In this interview and presentation, Theresa Kramer, MD, founder, CEO, and CMO of OcuFLOW, says company’s test of Choroidal Blood Flow could help physicians protect vision in people suffering from AMD, Diabetic Retinopathy, and Glaucoma. The technology also could save the healthcare system billions of dollars annually. The company is hoping to raise a Seed and Series A round in 2019.

Theresa Kramer, MD, founder, CEO, and CMO of OcuFLOW, answers three question about her company’s ability to assess Choroidal Blood Flow. Improving this measu...

12/10/2018

Eyevance Hits Ground Running with Licensing of Promising NEXAGON

Chief Scientific Officer Mark Jasek, PhD, introduces Eyevance’s innovative approach to ocular drug development. In this OIS Companies to Watch Presentation, Dr. Jasek details the company’s recent in-licensing of worldwide rights to NEXAGON, an exciting potential treatment for persistent corneal epithelial defect (PED) caused by thermal or chemical burns. In this presentation, Dr. Jasek shares the impressive results of the first compassionate ophthalmic therapeutic use of NEXAGON. “We’re very excited to have NEXAGON at Eyevance,” he says. The company plans to begin a Phase IIB clinical trial in early 2019.

Chief Scientific Officer Mark Jasek, PhD, introduces Eyevance’s innovative approach to ocular drug development. In this OIS Companies to Watch Presentation, ...

12/10/2018

HanAll PPT 2

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., outlines the company’s growing pipeline. In ophthalmology, HanAll, which is based in Seoul, has completed Phase II trials of HL036, an anti-TNF-alpha protein, for the treatment of . Applied twice a day, HL036 was shown to reduce symptoms and signs. The company is collaborating with Daewoong Pharmaceutical. HanAll may also test HL036 as a treatment for anterior uveitis, Wet AMD, and DME.

12/07/2018

In this week's podcast, we speak with Chris Wroten, OD, who left a chemical engineering career to pursue his early love of optometry. This path followed a few detours and disasters (of the natural kind), but he credits the ophthalmology community for seeing him through some challenging times. Dr. Wroten, who is helping to organize the upcoming [email protected] in New Orleans, sees smooth roads ahead for innovation in eye care. https://buff.ly/2BYQjwd

12/07/2018

Can HumanOptics change “Human optics history” with its artificial iris?

In this presentation, HumanOptics CEO Pierre Billardon, says the company’s CUSTOMFLEX ARTIFICIALIRIS could “change human optics history” and bring new hope to patients with systematic aniridia. The company has secured FDA approval for the implant, which is customized for each patient and compatible to other IOLs.

In this presentation, HumanOptics CEO Pierre Billardon, PhD, says the company’s CUSTOMFLEX ARTIFICIALIRIS could...

12/05/2018

HanAll Biopharma readying for Phase III Dry Eye Trial

HanAll Biopharma Co. Ltd. is readying for Phase III trials of HL036, an anti-TNF-alpha protein, for the treatment of . Watch Medical Advisor Edward Bernton, MD, present the company’s story and answer Three Critical Questions.

Edward Bernton, MD, medical advisor at HanAll Biopharma Co. Ltd., answers Three Critical Questions abo...